The additional liquidity will support both the continued development of Trinity Biotech’s innovative continuous glucose monitoring (CGM) technology and the Company Trinity Biotech’s patented ...

Diabetes CGM Developments We continue to progress ... Act”), including but not limited to statements related to Trinity Biotech’s cash position, financial resources and potential for future ...

With substantial progress in developing its differentiated and innovative CGM and its significant market potential, Trinity Biotech's board and management have determined that CGM technology and ...

Trinity Biotech Plc engages in the development, manufacture, and marketing of medical diagnostic products for the clinical laboratory and point-of-care segments of the diagnostic market.

Trinity Biotech plc (Nasdaq: TRIB) a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable ...

The additional liquidity will support both the continued development of Trinity Biotech’s innovative continuous glucose monitoring (CGM) technology and the Company Trinity Biotech’s patented ...

We continue to progress the development of our next generation continuous glucose monitoring ("CGM”) solution for diabetes management ... including but not limited to statements related to Trinity ...

The company aims to use this process to improve the functionality of its glucose biosensor in its next-gen CGM technology. Tuesday, Trinity Biotech plc (NASDAQ:TRIB) stock is trading higher with a ...